A Phase II Study Evaluating Efficacy and Safety of Hypomethylating Agent Guadecitabine in Combination with Carboplatin in Extensive Stage Small Cell Lung Cancer

Study on Investigational Medication Combination with Chemotherapy for Small Cell Lung Cancer

Recruiting
18 years - 100 years
All
1 Location

Brief description of study.

The purpose of this study is to find out if the combination of guadecitabine with carboplatin is better or worse than the usual approach for small cell lung cancer.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Small Cell Lung Cancer
  • Age: 18 years - 100 years
  • Gender: All

Inclusion Criteria

In order to be eligible to take part in this trial, patients must meet the following criteria:

  • Patient should not have received more than 1 prior line of chemotherapy (could have received immunotherapy which does not count as chemotherapy).
  • Male and female subjects of child- bearing potential must agree to use a double-barrier method of birth control from the screening visit through 3 months after the last dose of study drug.

For a full list of participation criteria, please visit clinicaltrials.gov.

Updated on 19 Feb 2024. Study ID: 1902370856 (LUN17-302)

This study investigates the effectiveness of combining an investigational medication with carboplatin for treating small cell lung cancer. Small cell lung cancer is a type of cancer that usually starts in the breathing tubes and spreads quickly. The study aims to compare this combination to the usual treatment methods to see which is more effective.

Participants in the study will receive either the investigational medication with carboplatin or the standard treatment. The study will involve regular monitoring and assessments to understand the effects and safety of the treatments.

  • Who can participate: Participants must not have had more than one prior chemotherapy treatment; previous immunotherapy is allowed. Male and female participants capable of having children must use effective birth control during and after the study.
  • Study details: Participants will be divided into study arms to receive either the investigational medication with carboplatin or the standard treatment, with regular monitoring to assess effects and safety.

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact label
Race
Ethnicity
Other language

Default Content Message Here